Subsequently, we delineated distinct T cell subtypes in the tumour by flow cytometry, including naïve, effector and memory CD4 + /CD8 + T cells following the initial and second anti-PD-1 combination therapies (Fig. 5a). The gene discussed is CD8A; the disease is neoplasm.